CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Encourages Investors to Contact the Firm

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics and AbbVie, focusing on potential conflicts and fairness of the transaction [1][7]. Group 1: Merger Details - Cerevel Therapeutics announced its acquisition by AbbVie on December 6, 2023, with AbbVie set to acquire all outstanding shares for $45.00 per share in cash [2]. - The total equity value of the transaction is approximately$8.7 billion, and it has been approved by the boards of directors of both companies [2]. Group 2: Legal Investigation - Bleichmar Fonti & Auld LLP believes that the board of directors of Cerevel Therapeutics was conflicted and engaged in an unfair process regarding the merger [7]. - Shareholders of Cerevel Therapeutics are encouraged to submit their information to explore their legal options [4][7]. Group 3: Law Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, having achieved significant recoveries in past cases [8].